{
  "id": 10001754,
  "title": "Inhaled drug shows promise for rare lung disease combination",
  "url": "https://urgent.news/2026/09/26/inhaled-drug-shows-promise-for-rare-lung-disease-combination",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-26T15:00:03.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-inhaled-drug-rare-lung-disease.html"
  },
  "original_language": "en",
  "account": "A novel inhaled drug called mosliciguat is showing promise in treating pulmonary hypertension linked to interstitial lung disease, according to a recent phase 2 clinical trial. This sGC activator, which activates a specific pathway in the lungs, has demonstrated consistent and significant effects in patients with PH-ILD. Unlike other sGC stimulators, mosliciguat targets dysfunctional forms of the enzyme, making it effective in conditions associated with oxidative stress. The drug was delivered via a dry-powder inhaler, allowing for targeted treatment with minimal systemic effects. In the phase 1b ATMOS study, patients experienced reduced pulmonary vascular resistance and improved exercise capacity after a single dose. The larger PHocus phase 2 trial, involving 135 patients across 20 countries, met its primary endpoint, showing a 56.3% reduction in pulmonary vascular resistance. The treatment effect was seen across various subgroups, and the drug also improved right-heart and pulmonary vascular function. The development of mosliciguat builds upon decades of research focusing on the nitric oxide-sGC-cGMP pathway, ultimately leading to the approval of riociguat for pulmonary arterial hypertension. The success of this trial highlights the importance of long-term translational research and the value of regional, national, and international collaboration in addressing rare diseases with unmet medical needs.",
  "summary": "A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced marked and consistent effects in a randomized phase 2 study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), one of the…",
  "key_points": [
    "Phase 2 trial PHocus met primary endpoint with 56.3% reduction in pulmonary vascular resistance.",
    "mosliciguat targets dysfunctional sGC enzyme, effective in oxidative stress-related conditions."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}